Gozee

Researchers are investigating whether the medicine vicadrostat, when taken together with empagliflozin, can lower the risk of heart-related problems in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. This study is a Phase III trial that compares the effects of vicadrostat plus empagliflozin to a placebo plus empagliflozin in people with these conditions. Participants are randomly assigned to one of two groups: one group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets that look like vicadrostat along with empagliflozin. All participants take one tablet daily for a period ranging from two and a half years up to four years and three months. Throughout the study, participants continue their usual medications for diabetes, high blood pressure, and cardiovascular disease. During up to 51 months of participation, participants visit the study site regularly where doctors collect health information and blood samples. Researchers track when participants experience cardiovascular events such as heart-related deaths or heart failure events. The study also monitors participants’ overall health and any side effects they may experience to assess the safety and effects of the treatments.

Researchers are studying adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG) who have completed previous related studies. The main goal is to evaluate the long-term safety and effectiveness of plozasiran, a drug given by injection, in these adults. Participants must meet specific health criteria, including controlled blood sugar levels and prior study completion, to join this open-label phase 3 extension trial. Eligible participants will receive plozasiran injections under the skin about every three months for two years. They will be advised to continue a low-fat diet throughout the study. This study includes adults from various countries who have met all previous study requirements or were prevented from randomization to avoid over-enrollment but still meet eligibility. Special criteria apply for some participants from earlier studies regarding their triglyceride levels and history of pancreatitis. During the study, participants will be monitored for any treatment-related side effects from the first dose through month 24. Researchers will assess safety by tracking adverse events and other health measures. Participants will also be counseled on medication adherence and diet, with ongoing evaluations to ensure their well-being throughout the two-year treatment period.

Human papillomavirus (HPV) infection is very common and often causes warts in people of all ages. This study evaluates the effectiveness of 2LVERU4 JUNIOR and 2LVERU4 treatments compared to a placebo in helping warts disappear. The trial aims to compare how well these treatments work by the end of a 6-month period, focusing on common, flat, and plantar warts caused by HPV. It is a phase 4, randomized, placebo-controlled, double-blind study involving patients aged 3 years and older. Participants will be assigned to one of two groups: one receiving 2LVERU4 JUNIOR or 2LVERU4 capsules, and the other receiving placebo capsules. Each participant will take one capsule daily, 15 to 30 minutes before breakfast on an empty stomach, following a sequence of capsules numbered 1 through 10, repeated continuously for 6 months. After the treatment phase, there is a 3-month follow-up period to monitor results and any possible recurrence of warts. During the study, patients will be monitored for wart disappearance, defined by normal skin color, texture, and touch at the wart site. Assessments will take place at 4 and 6 months after starting treatment, with additional evaluation of wart recurrence 3 months after treatment ends. Researchers will also compare pain levels related to warts and monitor safety throughout the study. The total study duration can last up to 45 months, including 36 months for patient enrollment and 9 months for follow-up.